Abstract
We present the case of a woman with a severe clinical history of antiphospholipid syndrome and persistent positivity for lupus anticoagulant, IgG anticardiolipin and IgG anti-β2Glycoprotein I antibodies. An acute clinical onset characterized by severe abdominal pain immediately followed by circulatory shock and histological colonic small vessel thrombosis pattern pointed to a diagnosis of ischemic colitis. The subsequent rapid onset of pulmonary alveolitis and heart failure associated to subendocardial hypoperfusion led to a diagnosis of definite catastrophic antiphospholipid syndrome (CAPS). Conventional triple therapy together with a broad-spectrum preventive antibiotic therapy were quickly initiated, and the outcome was favorable. We evaluated the patients with ischemic colitis in CAPS described in the literature between 1992 and May 2019 and our CAPS case. In accordance with the “two-hit” hypothesis and on the basis of the patients’ data, we would like to speculate that the colonic wall necrosis related to ischemic colitis damaged the intestinal barrier causing loss of resistance to bacteria and leading to endotoxemia and bacteremia with bacteria translocation through the circulatory stream to the lungs and heart. The bacteria acted as the priming factor which favored the binding of β2Glycoprotein I to the endothelium vessels in the colon, lungs, and heart following activation of anti-β2Glycoprotein I antibodies which attached to the domain I of β2Glycoprotein I. This was followed by complement activation which triggered the thrombotic and cytokine storm. If further clinical studies confirm this hypothesis, the treatment of CAPS could be more targeted and effective.
Similar content being viewed by others
References
Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, Jacobsen S, Lakos G, Tincani A, Kontopoulou-Griva I, Galeazzi M, Meroni PL, Derksen RH, de Groot PG, Gromnica-Ihle E, Baleva M, Mosca M, Bombardieri S, Houssiau F, Gris JC, Quéré I, Hachulla E, Vasconcelos C, Roch B, Fernández-Nebro A, Boffa MC, Hughes GR, Ingelmo M, Euro-Phospholipid Project Group (2002) Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46:1019–1027
Asherson RA, Cervera R, de Groot PG, Erkan D, Boffa MC, Piette JC, Khamashta MA, Shoenfeld Y, Catastrophic Antiphospholipid Syndrome Registry Project Group (2003) Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 12:530–534
Cervera R (2010) Catastrophic antiphospholipid syndrome (CAPS): update from the CAPS registry. Lupus 19:412–418
Rodríguez-Pintó I, Moitinho M, Santacreu I, Shoenfeld Y, Erkan D, Espinosa G, Cervera R, CAPS Registry Project Group (European Forum on Antiphospholipid Antibodies) (2016) Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of 500 patients from the international CAPS registry. Autoimmun Rev 15:1120–1124
Rodriguez-Pintó I, Espinosa G, Cervera R (2016) Catastrophic antiphospholipid syndrome: The current management approach. Best Pract Res Clin Rheumatol 30:239–249
Bucciarelli S, Erkan D, Espinosa G, Cervera R (2009) Catastrophic antiphospholipid syndrome: treatment, prognosis, and the risk of relapse. Clin Rev Allergy Immunol 36:80–84
Espinosa G, Rodríguez-Pintó I, Gomez-Puerta JA, Pons-Estel G, Cervera R, Catastrophic Antiphospholipid Syndrome (Caps) Registry Project Group (European Forum on Antiphospholipid Antibodies) (2013) Relapsing catastrophic antiphospholipid syndrome potential role of microangiopathic hemolytic anemia in disease relapses. Semin Arthritis Rheum 42:417–423
American Gastroenterological Association Medical Position Statement: guidelines on intestinal ischemia (2000) Gastroenterology 118:951–953
MacDonald PH (2002) Ischaemic colitis. Best Pract Res Clin Gastroenterol 16:51–61
Misiakos EP, Tsapralis D, Karatzas T, Lidoriki I, Schizas D, Sfyroeras GS, Moulakakis KG, Konstantos C, Machairas A (2017) Advents in the diagnosis and management of ischemic colitis. Front Surg 4:47
Tsimperidis AG, Kapsoritakis AN, Linardou IA, Psychos AK, Papageorgiou AA, Vamvakopoulos NC, Kyriakou DS, Potamianos SP (2015) The role of hypercoagulability in ischemic colitis. Scand J Gastroenterol 50:848–855
Suh DC, Kahler KH, Choi IS, Shin H, Kralstein J, Shetzline M (2007) Patients with irritable bowel syndrome or constipation have an increased risk for ischaemic colitis. Aliment Pharmacol Ther 25:681–692
O’Neill S, Elder K, Harrison SJ, Yalamarthi S (2012) Predictors of severity in ischaemic colitis. Int J Color Dis 27:187–191
Diaz Nieto R, Varcada M, Ogunbiyi OA, Winslet MC (2011) Systematic review on the treatment of ischaemic colitis. Color Dis 13:744–747
Bucciarelli S, Espinosa G, Cervera R, Erkan D, Gómez-Puerta JA, Ramos-Casals M, Font J, Asherson RA, European Forum on Antiphospholipid Antibodies (2006) Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum 54:2568–2576
Ruffatti A, De Silvestro G, Marson P, Tonello M, Calligaro A, Favaro M, Del Ross T, Hoxha A, Mattia E, Pengo V (2018) Catastrophic antiphospholipid syndrome: lessons from 14 cases successfully treated in a single center. A narrative report. J Autoimmun 93:124–130
Asherson RA (1992) The catastrophic antiphospholipid syndrome. J Rheumatol 19:508–512
Cervera R, Espinosa G, Cordero A, Oltra MR, Unzurrunzaga A, Rossiñol T, Plaza J, Bucciarelli S, Ramos-Casals M, Ingelmo M, Asherson RA, Font J, Catastrophic Antiphospholipid Syndrome (CAPS) Registry Project Group (2007) Intestinal involvement secondary to the antiphospholipid syndrome (APS): clinical and immunologic characteristics of 97 patients: comparison of classic and catastrophic APS. Semin Arthritis Rheum 36:287–296
Yotsueda H, Tsuruya K, Tokumoto M, Hirakata H, Iida M (2005) Catastrophic antiphospholipid antibody syndrome following initiation of hemodialysis. Clin Exp Nephrol 9:335–339
Koenig M, Roy M, Baccot S, Cuilleron M, de Filippis JP, Cathébras P (2005) Thrombotic microangiopathy with liver, gut, and bone infarction (catastrophic antiphospholipid syndrome) associated with HELLP syndrome. Clin Rheumatol 24:166–168
Jurgensen JS, Kettritz R, Schneider W, Koop H, Hildebrand TS, Frei U, Eckardt KU (2003) Catastrophic antiphospholipid syndrome masquerading as ischaemic colitis. Rheumatol Int 23:204–206
Bachmeyer C, Barrier A, Frazier A, Fulgencio JP, Lecomte I, Grateau G, Callard P (2006) Diffuse large and small bowel necrosis in catastrophic antiphospholipid syndrome. Eur J Gastroenterol Hepatol 18:1011–1014
Gru A, Dehner LP (2010) Catastrophic antiphospholipid syndrome in a child with trisomy 21. An acquired thrombopathy with a discussion of thrombopathies in childhood. Pediatr Dev Pathol 13:178–183
Townsend LR, Cotton JP, Altman DA, Gildenberg SR (2012) Catastrophic antiphospholipid syndrome. J Am Acad Dermatol 67:e214–e216
Añón R, Boscá MM, Sanchiz V, Tosca J, Almela P, Amorós C, Benages A (2006) Factors predicting poor prognosis in ischemic colitis. World J Gastroenterol 12:4875–4878
Mendoza-Pinto C, García-Carrasco M, Cervera R (2018) Role of infectious diseases in the antiphospholipid syndrome (including its catastrophic variant). Curr Rheumatol Rep 20:62
Fischetti F, Durigutto P, Pellis V, Debeus A, Macor P, Bulla R, Bossi F, Ziller F, Sblattero D, Meroni P, Tedesco F (2005) Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. Blood 106:2340–2346
Barratt-Due A, Floisand Y, Orrem HL, Kvam AK, Holme PA, Bergseth G, Tjønnfjord GE, Mollnes TE (2016) Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome. Rheumatology (Oxford) 55:1337–1339
Ruffatti A, Tarzia V, Fedrigo M, Calligaro A, Favaro M, Macor P, Tison T, Cucchini U, Cosmi E, Tedesco F, Angelini A, Gerosa G (2019) Evidence of complement activation in the thrombotic small vessels of a patient with catastrophic antiphospholipid syndrome treated with eculizumab. Autoimmun Rev 18:561–563
Durigutto P, Grossi C, Borghi MO, Macor P, Pregnolato F, Raschi E, Myers MP, de Groot PG, Meroni PL, Tedesco F (2019) New insight into antiphospholipid syndrome: antibodies to β2glycoprotein I-domain 5 fail to induce thrombi in rats. Haematologica 104:819–826
Grotz MR, Deitch EA, Ding J, Xu D, Huang Q, Regel G (1999) Intestinal cytokine response after gut ischemia: role of gut barrier failure. Ann Surg 229:478–486
Redan J, Rush B, Lysz T, Smith S, Machiedo G (1990) Organ distribution of gut-derived bacteria caused by bowel manipulation or ischemia. Am J Surg 159:85–90
Plonka AJ, Schentag JJ, Messinger S, Adelman MH, Francis KL, Williams JS (1989) Effects of enteral and intravenous antimicrobial treatment on survival following intestinal ischemia in rats. J Surg Res 46:216–220
Acknowledgments
The authors would like to thank Dr. Linda Inverso Moretti for editing the English version.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethics statement
All procedures performed in the study were in accordance with the ethical standards of the Institutional Review Board for observational studies and the Audit Committee of the University Hospital of Padua (reference number: 6894) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The patient gave informed consent for publication of this case study/report.
Disclosures
None.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Ruffatti, A., Calligaro, A., Lacognata, C.S. et al. Insights into the pathogenesis of catastrophic antiphospholipid syndrome. A case report of relapsing catastrophic antiphospholipid syndrome and review of the literature on ischemic colitis. Clin Rheumatol 39, 1347–1355 (2020). https://doi.org/10.1007/s10067-019-04888-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-019-04888-5